x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Few & Far Between: How Biotech Gets Built

Welcome to Few & Far Between! Chris O"Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.

science life sciences

All Episodes

00:48:25

Episode 47 - Marc Lajoie, CEO at Outpace Bio

Few & Far Between: How Biotech Gets Built ·

2024/12/31

"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how de novo proteins can be used to reprogram immune cells. Tune in today!

en

00:48:25

Episode 47 - Marc Lajoie, CEO at Outpace Bio

Few & Far Between: How Biotech Gets Built ·

2024/12/31

"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how de novo proteins can be used to reprogram immune cells. Tune in today!

en

00:37:26

Episode 46: Dr. Carsten Rudolph, CEO and Managing...

Few & Far Between: How Biotech Gets Built ·

2024/12/12

"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they are not destroyed during nebulization." - Dr. Carsten Rudolph, CEO and Managing Director at Ethris Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Dr. Carsten Rudolph, as they discuss the current state and bright future of nasal vaccine technology. Tune in today!

en

00:37:26

Episode 46: Dr. Carsten Rudolph, CEO and Managing...

Few & Far Between: How Biotech Gets Built ·

2024/12/12

"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they are not destroyed during nebulization." - Dr. Carsten Rudolph, CEO and Managing Director at Ethris Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Dr. Carsten Rudolph, as they discuss the current state and bright future of nasal vaccine technology. Tune in today!

en

00:44:29

Episode 44: Jonathan Scheiman, PhD, Co-Founder and...

Few & Far Between: How Biotech Gets Built ·

2024/10/23

"We don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Jonathan Scheiman, as they discuss microbiome solutions for next generation health and longevity. Tune in today!

en

00:44:29

Episode 44: Jonathan Scheiman, PhD, Co-Founder and...

Few & Far Between: How Biotech Gets Built ·

2024/10/23

"We don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Jonathan Scheiman, as they discuss microbiome solutions for next generation health and longevity. Tune in today!

en

00:39:18

Episode 43: Isaac Stoner, Co-founder and CEO at...

Few & Far Between: How Biotech Gets Built ·

2024/09/12

"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledge." - Isaac Stoner, Co-founder and CEO at Octagon TherapeuticsWelcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Isaac Stoner, as they discuss immunology, how to build a company, and financing in the biotech world. Tune in today!

en

00:39:18

Episode 43: Isaac Stoner, Co-founder and CEO at...

Few & Far Between: How Biotech Gets Built ·

2024/09/12

"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledge." - Isaac Stoner, Co-founder and CEO at Octagon Therapeutics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Isaac Stoner, as they discuss immunology, how to build a company, and financing in the biotech world. Tune in today!

en

00:36:14

Episode 42: Diana Azzam, PhD, Assistant Professor at...

Few & Far Between: How Biotech Gets Built ·

2024/07/16

“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent BiomedicalWelcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Diana Azzam, as they

en

00:36:14

Episode 42: Diana Azzam, PhD, Assistant Professor at...

Few & Far Between: How Biotech Gets Built ·

2024/07/16

“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Diana

en

00:35:24

Episode 41: Craig Serra, Head of Clinical Research...

Few & Far Between: How Biotech Gets Built ·

2024/05/23

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that can help." - Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Craig Serra, as they discuss improving and extending the life of every person with cancer and learning from those

en

00:35:24

Episode 41: Craig Serra, Head of Clinical Research...

Few & Far Between: How Biotech Gets Built ·

2024/05/23

"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that can help." -Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron HealthWelcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Craig Serra, as they discussimproving and extending the life of every person with cancer and learning from those experiences. Tune in

en

00:33:23

Episode 40: Professor Justin Stebbing,...

Few & Far Between: How Biotech Gets Built ·

2024/04/25

"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the UK's first NIHR Research Translational Professor of Oncology, Professor of Biomedical Sciences, Anglia Ruskin University, Cambridge.Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Professor Justin Stebbing, as they discuss insights into oncology, knowledge sharing, and the

en

00:33:23

Episode 40: Professor Justin Stebbing,...

Few & Far Between: How Biotech Gets Built ·

2024/04/25

"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the UK's first NIHR Research Translational Professor of Oncology, Professor of Biomedical Sciences, Anglia Ruskin University, Cambridge. Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Professor Justin Stebbing, as they discuss insights into oncology, knowledge

en

00:45:10

Episode 39: Dr. Keith Flaherty, Director of Clinical...

Few & Far Between: How Biotech Gets Built ·

2024/03/26

"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like a living cancer specimen." - Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Associate Physician of Hematology and Oncology at Mass. General Hospital. Welcome to the latest episode of Biorasi's Few & Far

en

00:45:10

Episode 39: Dr. Keith Flaherty, Director of Clinical...

Few & Far Between: How Biotech Gets Built ·

2024/03/26

"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like a living cancer specimen." - Dr. Keith Flaherty,Director of Clinical Research atMassachusetts General HospitalCancer Center, Professor of Medicine atHarvard Medical School, and Associate Physician ofHematologyandOncologyat Mass. General Hospital.Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris

en

00:38:27

Episode 38: Dr. Ole Isacson, Professor of Neurology...

Few & Far Between: How Biotech Gets Built ·

2024/02/22

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to really accelerate medicine's development." - Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School. Welcome to the February episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Ole Isacson, Professor of Neurology and Neuroscience at Harvard Medical School and Biorasi

en

00:38:27

Episode 38: Dr. Ole Isacson, Professor of Neurology...

Few & Far Between: How Biotech Gets Built ·

2024/02/22

"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to really accelerate medicine's development." - Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School.Welcome to the February episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Ole Isacson,Professor of Neurology and Neuroscience at Harvard Medical School and Biorasi Scientific Advisory Board

en

00:41:31

Episode 37: Will Greene, Prader-Willi Syndrome...

Few & Far Between: How Biotech Gets Built ·

2024/01/24

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." -Will Greene, Prader-Willi syndrome patient advocate and Healthcare Engagement Lead at Roche Welcome to Biorasi's first Few & Far Between episode of 2024! Join host Chris O'Brien and guest Will Greene,Prader-Willi syndrome (PWS) patient advocate and Healthcare Engagement Lead at Roche, as they explore rare disease diagnoses and the importance of newborn screening as

en

00:41:31

Episode 37: Will Greene, Prader-Willi Syndrome...

Few & Far Between: How Biotech Gets Built ·

2024/01/24

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will Greene, Prader-Willi syndrome patient advocate and Healthcare Engagement Lead at Roche Welcome to Biorasi's first Few & Far Between episode of 2024! Join host Chris O'Brien and guest Will Greene, Prader-Willi syndrome (PWS) patient advocate and Healthcare Engagement Lead at Roche, as they explore rare disease diagnoses and the importance

en

121 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter